Open AccessGene therapy and nasopharyngeal carcinoma
Author(s) -
Jonathan Hughes,
Ghassan Alusi,
Yaohe Wang
Publication year - 2012
Publication title -
rhinology (amsterdam. online)/rhinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.275
H-Index - 57
eISSN - 1996-8604
pISSN - 0300-0729
DOI - 10.4193/rhino11.239
Subject(s) - medicine , nasopharyngeal carcinoma , genetic enhancement , oncology , head and neck cancer , chemotherapy , radiation therapy , gene , intensive care medicine , genetics , biology
In 2003, a non-replicating adenoviral gene therapy product received the world`s first government licence for the treatment of head and neck cancer. Two years later approval was granted to a replication-selective adenovirus for the treatment of nasopharyngeal carcinoma in combination with chemotherapy. This review introduces the reader to gene therapy as an emerging treatment modality, and outlines its application to the management of nasopharyngeal carcinoma by examining recent pre-clinical and clinical research.